Key facts
- This page summarizes Paul B. Manning's Form 4 filing for Verrica Pharmaceuticals Inc. (VRCA).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 25 Nov 2025, 19:00.
Paul B. Manning - 25 Nov 2025 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- VRCA
- Reported as of
- 25 Nov 2025
- Net transaction value
- +$17,505,157
- SEC form
- 4
- Accepted by SEC
- 25 Nov 2025, 19:00:09 UTC
- Prior SEC filing
- 02 Sep 2025
- Next SEC filing
- 12 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Ballantyne, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Paul B. Manning filed Form 4 for Verrica Pharmaceuticals Inc. (VRCA) on 25 Nov 2025.
Change
- Previous filing in this sequence was filed on 02 Sep 2025.
- Current net transaction value: +$17,505,157.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001494695
Primary reporting owner
Manning Paul B
- Relationship
- Director, 10%+ Owner
- Address
- 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE
- Signature
- /s/ Mark Ballantyne, Attorney-in-fact
- Signature date
- 25 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRCA
transaction
Common Stock
Purchase
- Transaction value
- $5,835,050
- Shares
- +1,375,380
- Change %
- +53%
- Price
- $4.24
- Shares after
- 3,958,189
- Date
- 25 Nov 2025
- Ownership
- Direct
- Footnotes
- F1, F2
VRCA
transaction
Common Stock
Purchase
- Transaction value
- $11,670,108
- Shares
- +2,750,762
- Change %
- +460%
- Price
- $4.24
- Shares after
- 3,348,372
- Date
- 25 Nov 2025
- Ownership
- See footnote
- Footnotes
- F1, F3
VRCA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 89,187
- Date
- 25 Nov 2025
- Ownership
- By trust
- Footnotes
- F1, F4
VRCA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 89,187
- Date
- 25 Nov 2025
- Ownership
- By trust
- Footnotes
- F1, F4
VRCA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 89,187
- Date
- 25 Nov 2025
- Ownership
- By trust
- Footnotes
- F1, F4
VRCA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 332,433
- Date
- 25 Nov 2025
- Ownership
- By trust
- Footnotes
- F1, F5
VRCA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 25,663
- Date
- 25 Nov 2025
- Ownership
- See footnote
- Footnotes
- F1, F6
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRCA
transaction
Derivative
Series C Warrant (right to buy)
Purchase
- Transaction value
- Shares
- +343,845
- Change %
- Price
- Shares after
- 343,845
- Date
- 25 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 343,845
- Exercise price
- $6.32
- Footnotes
- F2, F7, F8
VRCA
transaction
Derivative
Series C Warrant (right to buy)
Purchase
- Transaction value
- Shares
- +687,690
- Change %
- Price
- Shares after
- 687,690
- Date
- 25 Nov 2025
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 687,690
- Exercise price
- $6.32
- Footnotes
- F3, F7, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.
Footnote F2
The shares are held by Mr. Manning jointly with his spouse.
Footnote F3
The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.
Footnote F4
These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Footnote F5
The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Footnote F6
The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.
Footnote F7
Immediately exercisable.
Footnote F8
The reported securities are included within 1,375,380 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
Footnote F9
The reported securities are included within 2,750,762 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.